What is LUCA Science?
LUCA Science operates at the cutting edge of cellular medicine, specifically focusing on the development of mitochondria therapies. As a pre-clinical stage biopharmaceutical entity, the company leverages the fundamental role of mitochondria in cellular energy production to address unmet medical needs. By isolating and stabilizing these organelles, LUCA Science aims to restore cellular function in diseased tissues, offering a novel approach to regenerative medicine and chronic disease management. Its strategic location in Tokyo provides a unique advantage, allowing the firm to tap into Japan's sophisticated life sciences ecosystem and collaborative research networks.
How much funding has LUCA Science raised?
LUCA Science has raised a total of $40.1M across 2 funding rounds:
Series A
$9.8M
Series B
$30.3M
Series A (2020): $9.8M with participation from Axil Capital Advisors KK/ Axil Capital Partners
Series B (2022): $30.3M led by QB Capital/NCB Venture Capital, DCI WALBRIDGE PARTNERS, SMBC Venture Capital, 4BIO Capital, Fast Track, Asahi Kasei Pharma America (AKP America), and Nissay Capital
Key Investors in LUCA Science
4BIO Capital
4BIO Capital is a London-based venture capital firm specializing in life sciences investments. The company focuses on advanced therapies that address significant unmet medical and social needs, including gene and cell therapy.
Asahi Kasei Pharma America (AKP America)
Asahi Kasei Pharma America is a biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients throughout the world as a subsidiary of Asahi Kasei Pharma Corp.
Nissay Capital
Nissay Capital is a Japan-based global administration and monetary system counseling firm that provides strategic support and investment to companies facing significant industry change.
What's next for LUCA Science?
With the successful closure of its recent financing, LUCA Science is poised to transition from foundational research into more advanced pre-clinical milestones. The strategic allocation of these funds will likely prioritize the scaling of manufacturing processes for its mitochondrial products and the expansion of its internal research team. Furthermore, the involvement of high-profile life sciences investors suggests a clear roadmap toward future clinical trials and potential regulatory filings. As the company continues to refine its therapeutic delivery mechanisms, it remains a critical player to watch within the global biotech landscape, particularly as it seeks to validate its platform's efficacy in human-relevant models and establish long-term commercial viability in the competitive regenerative medicine market.
See full LUCA Science company page
